Interview with Manuel Reiberg, Manager Company Operations, Daiichi Sankyo…
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
Address: Effingergasse 21, 1160 Vienna,Austria
Tel: +43 1 48586420
Web: http://www.daiichi-sankyo.at/
Daiichi Sankyo Austria GmbH is the Austrian affiliate of Daiichi Sankyo, a global pharmaceutical company that focuses on researching and marketing innovative medications. The company’s roots extend back to 1899 and the early days of industrialization of the pharmaceutical sector.
The company itself was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly €8.6 billion in fiscal year 2011, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies. The company does business in nearly 60 countries around the world. Daiichi Sankyo’s world headquarters are in Tokyo, Japan.
The company’s roots in Europe extend back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. The company currently does business in 12 European countries including Austria. With nearly 2,500 employees, Daiichi Sankyo has been one of the strongest Japanese pharmaceutical companies located in Europe.
Striving for innovation is a central task of Daiichi Sankyo. Innovation is the fundamental requirement for achieving the corporate goal of developing pharmaceutical products that are the best in their class or for establishing a new class of active ingredients. Furthermore, the commitment to fulfill or exceed the high expectations of stakeholders regarding corporate services, information and organizational processes is based on innovation as a fundamental principle.
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified unmet medical needs of doctors and patients. In its research, the company aims to develop drugs that are either “Best-in-Class” or create a new class of therapeutic solutions.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, Daiichi Sankyo is engaged in the development of treatments for patients with thrombotic disorders and is focused on the discovery of novel oncology and cardiovascular-metabolic therapies.egulations. Detailed information about such drugs, such as the performance of our products may be provided only to medical professionals. For this reason, we can only give you an overview of our main products.
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
Dr. Wolfgang Schnitzel, general manager of Shire Austria, and Karl-Heinz Hofbauer, site lead Vienna and managing director for the Technical Operations business, discuss the huge impact of Shire’s 32 billion…
Maria Seriakov, CEO and founder of M bioserviceS, a young Austrian company dealing globally that specialises in logistics, regulatory affairs and quality control of biologics, discusses the challenges of navigating…
Prof. Ruth Ladenstein, executive director of the Medicines for Children Research Organisation (OKIDS) in Austria, explains OKIDS’ drive to ensure drugs are paediatric specific by conducting child-specific clinical trials. Furthermore,…
Philipp Lindinger, managing director of Austromed, the Austrian association for medical devices and in-vitro diagnostics, discusses the organization’s purpose, the impact of European regulation on medical devices on the sector,…
Martin Prinz, CTO of Croma-Pharma, a family-owned Austrian aesthetic dermatology company, discusses the evolution of the company over the years and their specialist, ever-expanding portfolio. Additionally, he documents the role…
Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of…
Michael Stampfer, managing director of the Vienna Science and Technology Fund (WWTF), the only private, non-profit organization in Vienna dedicated to funding scientific research, discusses the challenges scientific research faces…
Michaela Latzelsberger, country manager of Coloplast Austria, a Danish medical device company focused on ostomy, continence and wound care, discusses the challenges of launching innovative medical devices on the Austrian…
Urs Weber, general secretary of the Swiss Chamber of Commerce in Austria, discusses the role of the chamber as a networking facilitator between Austrian and Swiss companies as well as…
Heidrun Katholnigg, executive director of global clinical development Europe for Celerion, a global CRO that specialises in phase I, II and III clinical trials, discusses the acquisition of Assign Group…
Ulrich Schlick, deputy managing director of the German Chamber of Commerce in Austria, discusses the Chamber’s role in facilitating business opportunities for German companies in Austria and vice versa. He…
Bernd Grabner, board member of Jacoby GM pharma, a leading Austrian wholesaler, provides an in-depth look into the historical merger of family owned Jacoby, GM pharma and Kӧgl Pharma as…
See our Cookie Privacy Policy Here